A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan-Reference-Cited by-同舟云学术

A cost-effectiveness analysis of revaccination and catch-up strategies with the 23-valent pneumococcal polysaccharide vaccine (PPV23) in older adults in Japan

Published:2018-05-03 Issue:7 Volume:21 Page:687-697
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Jiang Yiling¹,Yang Xiaoqin²,Taniguchi Kazuko³,Petigara Tanaz²,Abe Machiko³

Affiliation:

1. Merck Sharp & Dohme Ltd., Hoddesdon, Hertfordshire, UK;

2. Merck & Co., Inc., Kenilworth, NJ, USA;

3. MSD K.K., Tokyo, Japan

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2018.1465272

Reference52 articles.

1. The remaining challenges of pneumococcal disease in adults

2. Pediatric Invasive Pneumococcal Disease in the United States in the Era of Pneumococcal Conjugate Vaccines

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of pediatric immunization program with 15-valent pneumococcal conjugate vaccine in Japan;Journal of Medical Economics;2023-08-18

2. Status of Herpes Zoster and Herpes Zoster Vaccines in 2023: A position paper;Revista Española de Quimioterapia;2023-02-08

3. A global agenda for older adult immunization in the COVID-19 era: A roadmap for action;Vaccine;2021-08

4. Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China;Frontiers in Public Health;2021-05-24

5. The value of decreasing the duration of the infectious period of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection;PLOS Computational Biology;2021-01-07